Cingulate Inc WT (CINGW)

$0.06 +0.00 (3.63%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -23.53M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 3,100
Avg Vol 175,240
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 17%
Beta N/A
Analysts Sell
Price Target N/A

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In...

Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
Latest News on CINGW
Six new option listings on April 22nd

2026-04-22T13:47:28.000Z - 20 days ago

Six new option listings on April 22nd

NUCL VGNT XNDU

Cingulate files to sell 4.21M shares of common stock for holders

2026-04-14T21:30:17.000Z - 4 weeks ago

Cingulate files to sell 4.21M shares of common stock for holders

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Apr 6, 2026, 4:34 PM EDT - 5 weeks ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Cingulate price target lowered to $14 from $16 at Roth Capital

2026-03-22T22:30:08.000Z - 7 weeks ago

Cingulate price target lowered to $14 from $16 at Roth Capital

Cingulate files to sell 3.5M shares of common stock for holders

2026-03-20T11:46:09.000Z - 7 weeks ago

Cingulate files to sell 3.5M shares of common stock for holders

Cingulate announces U.S. patent notice of allowance

2026-03-18T12:12:11.000Z - 2 months ago

Cingulate announces U.S. patent notice of allowance

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

2026-03-18T12:05:55.000Z - 2 months ago

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

Cingulate sees cash runway into late 4Q26

2026-03-18T12:05:40.000Z - 2 months ago

Cingulate sees cash runway into late 4Q26

Why did Cingulate stock skyrocket today?

Mar 16, 2026, 1:26 PM EDT - 2 months ago

Why did Cingulate stock skyrocket today?

Cingulate files $200M mixed securities shelf

2026-01-12T22:15:20.000Z - 4 months ago

Cingulate files $200M mixed securities shelf

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T12:40:10.000Z - 6 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T00:55:07.000Z - 6 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 6 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

2025-11-13T13:16:41.000Z - 6 months ago

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

Cingulate names Downey as CCO to lead launch prep for CTx-1301

2025-11-10T13:25:38.000Z - 6 months ago

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

2025-10-28T12:27:02.000Z - 7 months ago

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 7 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate price target raised to $17 from $10 at Roth Capital

2025-10-15T01:25:08.000Z - 7 months ago

Cingulate price target raised to $17 from $10 at Roth Capital

Cingulate announces FDA accepted for review the NDA for CTx-1301

2025-10-14T12:05:41.000Z - 7 months ago

Cingulate announces FDA accepted for review the NDA for CTx-1301

Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences

2025-09-17T12:50:16.000Z - 8 months ago

Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 8 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 9 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate price target lowered to $10 from $11 at Roth Capital

2025-08-20T21:40:18.000Z - 9 months ago

Cingulate price target lowered to $10 from $11 at Roth Capital

Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year

2025-08-19T12:50:08.000Z - 9 months ago

Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 9 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate places CEO Schaffer on administrative leave

2025-08-15T13:10:52.000Z - 9 months ago

Cingulate places CEO Schaffer on administrative leave

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 9 months ago

Cingulate Provides Management Team Update

Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301

2025-08-08T19:25:13.000Z - 9 months ago

Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 10 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 11 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 2 years ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 2 years ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 2 years ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 2 years ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 3 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 3 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest